Literature DB >> 9269699

ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.

F G van der Kleij1, G J Navis, R T Gansevoort, J E Heeg, H Scheffer, D de Zeeuw, P E de Jong.   

Abstract

BACKGROUND: The renal response to ACE inhibition is known to vary between individuals. The ACE genotype is a determinant of the ACE concentrations in plasma and tissue, and therefore might affect the renal response to ACE inhibition in renal patients.
METHODS: To test this hypothesis we studied the short-term response to ACE inhibition (enalapril or lisinopril 10/20 mg/d) in 61 stable proteinuric patients (> 1.0 g/day) in relation to the ACE genotype (DD N = 16, ID N = 32, II N = 13).
RESULTS: Baseline values were not significantly different for the three groups. ACE inhibition significantly reduced proteinuria, mean arterial pressure, GFR and FF in all genotype groups. The reduction in proteinuria, MAP, GFR and FF was not different between the genotype groups. ERPF increased significantly and to the same extent in all three groups.
CONCLUSIONS: We conclude that in proteinuric patients the short-term responses to ACE inhibition of proteinuria, blood pressure, and renal haemodynamics are not determined by ACE genotype. Thus, ACE gene polymorphism does not account for the known interindividual variation in the short-term renal response to ACE inhibition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269699

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

Review 1.  ACE inhibitors and the kidney. A risk-benefit assessment.

Authors:  G Navis; H J Faber; D de Zeeuw; P E de Jong
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

2.  Pharmacogenetics of cardiovascular drug therapy.

Authors:  Bas J M Peters; Olaf H Klungel; Anthonius de Boer; Bruno H Ch Stricker; Anke-Hilse Maitland-van der Zee
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 3.  Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.

Authors:  Piero Ruggenenti; Paola Bettinaglio; Franck Pinares; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-11       Impact factor: 8.237

4.  High prevalence of ACE DD genotype among north Indian end stage renal disease patients.

Authors:  Gaurav Tripathi; Poonam Dharmani; Faisal Khan; R K Sharma; Vinod Pandirikkal; Suraksha Agrawal
Journal:  BMC Nephrol       Date:  2006-10-17       Impact factor: 2.388

Review 5.  ACE insertion/deletion polymorphism and diabetic nephropathy: clinical implications of genetic information.

Authors:  Sung-Kyu Ha
Journal:  J Diabetes Res       Date:  2014-12-23       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.